Key Drivers
- Strong liquidity
- Ongoing cash burn
- Significant dilution
AIAI Summary
ELVN is a well-funded, high-expectation clinical execution story—not a financing-risk biotech—so investors should focus on whether ELVN-001's Phase 1 differentiation holds in pivotal CML trials, as its ~$4.2B enterprise value leaves limited room for disappointment despite runway into 2030.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Ongoing cash burn
- •Significant dilution
ELVN is well-capitalized and debt-free, but persistent losses, negative cash flow, dilution, and a premium valuation unsupported by revenue warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Persistent downtrend
- •Oversold momentum
- •Critical support
ELVN remains in a bearish last-month trend, but oversold RSI near support at $49.12 may support a rebound if it clears $50.24; otherwise, a break below support signals further weakness.
Sharp decline between 2026-09-15 and 2026-09-16
Sentiment & News
Key News Insights:
- •BlackRock stake
- •Strong Phase 1
- •Cash runway
BlackRock's 7.16% stake, strong ELVN-001 Phase 1 data, and $895M cash runway bolster Enliven's clinical and financial outlook.
The developments are positive for Enliven's valuation outlook and ENABLE-2 trial execution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings